New era for novel CNS drug development
- PMID: 22157855
- PMCID: PMC3238073
- DOI: 10.1038/npp.2011.186
New era for novel CNS drug development
References
-
- Keller M, Montgomery S, Ball W, Morrison M, Snavely D, Liu G, et al. Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol Psychiatry. 2006;59:216–223. - PubMed
-
- Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg ST, et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov. 2010;9:204–214. - PubMed
-
- Pinard E, Alanine A, Alberati D, Bender M, Borroni E, Brom V, et al. Selective GlyT1 inhibitors: discovery of [4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia. J Med Chem. 2010;53:4603–4614. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources